CELU - יחס חוב להיוון בספרים celularity.com

Celularity Inc. (CELU) reduces medical risks by developing placenta-derived cell therapies for tissue regeneration and oncology. Financial dependency levels based on balance sheet capital on the GURU.Markets chart show a metric value of 0.00. While cryopreservation patents ensure product longevity, high innovation costs coupled with low biobanking revenues create a significant cash gap.

This indicator measures the proportion of borrowed funds relative to the company's equity. The calculation is based on the ratio of total liabilities to the book value of assets minus debt. By analyzing the company's debt in proportion to its book capitalization, an investor assesses financial stability and leverage risks. For Celularity Inc. (CELU), such a balance is critical when scaling cellular products. This allows the company to finance costly developments in regenerative medicine without creating an excessive debt burden.